Even though HSCT has a significant role in consolidating FLT3-ITD positive AML patients [12,30], no study analyzed the role of the allelic ratio in this context, leaving substantial knowledge gaps concerning factors associated with outcomes following HSCT in these patients [30]. The gene discussed is FLT3; the disease is acute myeloid leukemia.